Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis
Open Access
- 7 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (1), 65-73
- https://doi.org/10.1038/bjc.2011.143
Abstract
Prostate-specific antigen (PSA) screening has low specificity. Assessment of methylation status in body fluids may complement PSA screening if the test has high specificity. The purpose of this study was to conduct a meta-analysis of the sensitivity and specificity for prostate cancer detection of glutathione-s-transferase–π (GSTP1) methylation in body fluids (plasma, serum, whole blood, urine, ejaculate, and prostatic secretions). We conducted a comprehensive literature search on Medline (Pubmed). We included studies if they met all four of the following criteria: (1) measurement of DNA methylation in body fluids; (2) a case-control or case-only design; (3) publication in an English journal; and (4) adult subjects. Reviewers conducted data extraction independently using a standardised protocol. Twenty-two studies were finally included in this paper. Primer sequences and methylation method in each study were summarised and evaluated using meta-analyses. This paper represents a unique cross-disciplinary approach to molecular epidemiology. The pooled specificity of GSTP1 promoter methylation measured in plasma, serum, and urine samples from negative-biopsy controls was 0.89 (95% CI, 0.80–0.95). Stratified analyses consistently showed a high specificity across different sample types and methylation methods (include both primer sequences and location). The pooled sensitivity was 0.52 (95% CI, 0.40–0.64). The pooled specificity of GSTP1 promoter methylation measures in plasma, serum, and urine was excellent and much higher than the specificity of PSA. The sensitivity of GSTP1 was modest, no higher than that of PSA. These results suggest that measurement of GSTP1 promoter methylation in plasma, serum, or urine samples may complement PSA screening for prostate cancer diagnosis.Keywords
This publication has 31 references indexed in Scilit:
- DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non‐invasive detectionThe Prostate, 2009
- Inflammatory, Lipid, Thrombotic, and Genetic Markers of Coronary Heart Disease Risk in the Women's Health Initiative Trials of Hormone TherapyJAMA Internal Medicine, 2008
- Methylation‐Specific Sequencing of GSTP1 Gene Promoter in Circulating/Extracellular DNA from Blood and Urine of Healthy Donors and Prostate Cancer PatientsAnnals of the New York Academy of Sciences, 2008
- CpG Island Hypermethylation Profile in the Serum of Men With Clinically Localized and Hormone Refractory Metastatic Prostate CancerJournal of Urology, 2008
- Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinomaCancer Detection Prevention, 2007
- CpG Island hypermethylation in cell‐free serum DNA identifies patients with localized prostate cancerThe Prostate, 2007
- Promoter hypermethylation in circulating blood cells identifies prostate cancer progressionInternational Journal of Cancer, 2007
- High Concordance of Gene Methylation in Post-Digital Rectal Examination and Post-Biopsy Urine Samples for Prostate Cancer DetectionJournal of Urology, 2006
- Cell‐free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast CancerAnnals of the New York Academy of Sciences, 2006
- Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control SubjectsJournal of Clinical Oncology, 2005